Andri Papakonstantinou has been awarded the Pfizer and Swedish Society of Oncology's (SOF) research scholarship in oncology ...

At the Tandem Meetings 2025, researchers presented a study of scalp cooling in patients undergoing chemotherapy and ASCT.

The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...

The global breast cancer therapeutics market is expected to grow from US$ 31.07 billion in 2022 to US$ 63.9 billion by 2030, ...

Pfizer Inc. is currently one of the top profitable value stocks to consider. Its forward P/E ratio of 8.66 makes it a highly attractive investment option. Pfizer's recent acquisition of Seagen has ...

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Trump administration withdraws Dave Weldon's CDC nomination, while Pfizer/Arvinas report mixed breast cancer data and Roche/Zealand Pharma form $5.3B obesity partnership.

Cryotherapy is emerging as a promising strategy to prevent chemotherapy-induced peripheral neuropathy, but adoption in clinical practice remains limited.

Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...

Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...

DelveInsight's "VERZENIO Market Size, Forecast, and Market Insight Report" highlights the details around VERZENIO, which is a targeted treatment known as ...